GLP1R variant found in 40% of East Asians
Each copy linked to an additional 0.53-percentage-point reduction in glycated hemoglobin
"Mechanism that promotes insulin secretion identified"

A genetic factor that may explain why patients experience different improvements in blood glucose levels even when using the same glucagon-like peptide-1 (GLP-1)-based diabetes treatment has been identified. Patients with a specific genetic variant common among East Asians saw greater reductions in blood glucose after treatment, and their pancreatic insulin-secreting function was also relatively well preserved over the long term.


Seoul National University Hospital announced on November 16 the results of a study by a joint research team from the hospital, led by Professor Kwak Suheon of its Division of Endocrinology and Metabolism; Professor Kim Jongil of the Institute of Genomic Medicine at Seoul National University College of Medicine; Professor Park Kyungsoo of the Division of Endocrinology and Metabolism at Konkuk University Medical Center; and Mayo Clinic in the United States. The team analyzed the effects of the GLP1R R131Q (rs3765467) genetic variant on responses to GLP-1-based treatments and pancreatic function.


From left: Professor Kwak Sooheon, Department of Endocrinology and Metabolism, Seoul National University Hospital; Professor Kim Jongil and Dr. Lee Hyeonseok, Institute of Genomic Medicine, Seoul National University College of Medicine; and Professor Park Kyungsoo, Department of Endocrinology and Metabolism, Konkuk University Medical Center. Seoul National University Hospital

From left: Professor Kwak Sooheon, Department of Endocrinology and Metabolism, Seoul National University Hospital; Professor Kim Jongil and Dr. Lee Hyeonseok, Institute of Genomic Medicine, Seoul National University College of Medicine; and Professor Park Kyungsoo, Department of Endocrinology and Metabolism, Konkuk University Medical Center. Seoul National University Hospital

View original image

This variant is known to be present in about 40% of East Asians. It has been reported to lower the risk of developing type 2 diabetes, but its actual effects on pancreatic function and drug response have not been clearly established.


The research team first analyzed 177 patients with type 2 diabetes who had received GLP-1-based treatment for at least six months at Seoul National University Hospital, Seoul National University Bundang Hospital, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, and Gachon University Gil Medical Center. The results showed that each copy of the genetic variant was associated with an additional average reduction of 0.53 percentage points in glycated hemoglobin.


Glycated hemoglobin decreased by an average of 0.57 percentage points in patients without the variant, compared with 1.05 percentage points in patients with one copy and 1.30 percentage points in those with two copies. The proportions of patients who reached a glycated hemoglobin level of 7% or lower after six months of treatment also differed: 8.4% among those without the variant, 22% among those with one copy, and 43% among those with two copies. However, weight loss did not differ by genotype. About 80% of the patients analyzed received dulaglutide.


Similar results were found in long-term follow-up. After tracking 6,373 Korean people without diabetes for 20 years, the research team found that the disposition index, which reflects insulin-secreting function, decreased by 37% in those without the variant, 35% in those with one copy, and 30% in those with two copies. The more copies of the variant a person had, the smaller the decline in pancreatic beta-cell function.


Cell experiments also revealed the mechanism behind these differences. When stimulated by the drug, the variant GLP-1 receptor sent stronger signals that promote insulin secretion. In contrast, it bound less readily to beta-arrestin-2, which suppresses receptor signaling. The signaling capacity of the variant receptor was 1.43 times that of the normal receptor when stimulated by GLP-1 and 1.28 times as high when stimulated by semaglutide.


Experiments involving people showed the same trend. In a hyperglycemic clamp test conducted at Mayo Clinic in the United States on 17 people without diabetes, insulin secretion tended to increase more in variant carriers after they received liraglutide. In an islet experiment using samples obtained from 21 surgical patients at Seoul National University Hospital, the increase in insulin secretion in response to drug stimulation was greater among those with more copies of the variant.


Schematic of a study analyzing the function of the GLP1R R131Q variant. Seoul National University Hospital.

Schematic of a study analyzing the function of the GLP1R R131Q variant. Seoul National University Hospital.

View original image

The research team said the findings provide evidence that genetic information can help explain differences in individual responses to GLP-1-based treatments. Professor Kwak said, "We have established a basis for using genetic information to explain why blood glucose levels fall by different amounts in different patients, even when they take the same drug. The findings may also help us understand why responses to this drug have been reported to be better among East Asians."



Professor Park said, "We confirmed from multiple perspectives that a genetic variant common among East Asians is associated with both the preservation of pancreatic function and responses to GLP-1 treatments. After further validation, including through randomized clinical trials, we aim to develop these findings into evidence for precision diabetes treatment tailored to East Asians." The results were published online in the latest issue of Diabetes Care, the official journal of the American Diabetes Association.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing